STOCK TITAN

Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a biopharmaceutical company, announced its participation in the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day on November 15, 2022, in New York City. Senior leadership will engage in a fireside chat at 2:45 PM ET. A webcast will be available on their website for 30 days post-event. Longboard focuses on developing transformative medicines for neurological diseases, with key product candidates LP352, LP659, and LP143 under evaluation.

Positive
  • None.
Negative
  • None.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day, which is taking place November 14-15, 2022, in New York City.

Presentation Details:
Title: Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day (In-person)
Details: Participating in a fireside chat on Tuesday, November 15, 2022 at 2:45pm ET
Location: Track 1 - Louis XVI A

To access a webcast of the presentation, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The fireside chat will be webcast live and archived on the website for at least 30 days following the event.

About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conferences, Longboard’s clinical and preclinical programs, ability to develop and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:

Megan E. Knight

Head of Investor Relations

IR@longboardpharma.com

619.592.9775

Source: Longboard Pharmaceuticals, Inc.

FAQ

When is Longboard Pharmaceuticals participating in the Guggenheim Healthcare Talks?

Longboard Pharmaceuticals will participate in the Guggenheim Healthcare Talks on November 15, 2022.

What time will Longboard Pharmaceuticals' presentation take place?

The presentation will take place at 2:45 PM ET.

Where is the Guggenheim Healthcare Talks event held?

The event is held in New York City.

What is the focus of Longboard Pharmaceuticals?

Longboard Pharmaceuticals focuses on developing medicines for neurological diseases.

How can I access the webcast of Longboard Pharmaceuticals' presentation?

The webcast can be accessed on the Events & Presentations page of Longboard's Investors Relations website.

Longboard Pharmaceuticals, Inc.

NASDAQ:LBPH

LBPH Rankings

LBPH Latest News

LBPH Stock Data

2.34B
33.87M
1.2%
121.42%
4.94%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA